NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → How Biden has already won 2024 (From Porter & Company) (Ad) Free HIMS Stock Alerts $19.42 -0.95 (-4.66%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$18.89▼$20.3850-Day Range$11.25▼$20.3652-Week Range$5.65▼$21.44Volume15.99 million shsAverage Volume6.72 million shsMarket Capitalization$4.17 billionP/E RatioN/ADividend YieldN/APrice Target$15.69 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside19.2% Downside$15.69 Price TargetShort InterestBearish14.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 17 Articles This WeekInsider TradingSelling Shares$8.46 M Sold Last QuarterProj. Earnings Growth83.33%From $0.18 to $0.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector589th out of 929 stocksOffices & Clinics Of Medical Doctors Industry4th out of 8 stocks 2.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.69% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 20.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 3.0 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Hims & Hers Health this week, compared to 8 articles on an average week.Search Interest92 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 360% compared to the previous 30 days.MarketBeat Follows45 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 105% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,464,914.00 in company stock.Percentage Held by Insiders17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 83.33% in the coming year, from $0.18 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -1,942.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -1,942.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 12.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesMay 31 at 7:04 AM | insidertrades.comSoleil Boughton Sells 2,502 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMay 30 at 7:00 AM | marketbeat.comCall Option Volumes Spiked For These 3 StocksAs the saying goes, always follow the money. This time, investors can follow the proverbial big players through an options activity screener, spotting unusual trends in how markets are betting.May 30 at 7:00 AM | marketbeat.comCall Option Volumes Spiked For These 3 Stocks (HIMS)Option traders decided to plow into call contracts for these three stocks, investors can see the specific fundamental reasons behind this decisionMay 28 at 8:41 AM | marketbeat.comLifeMD Can Surge on Its GLP-1 Offerings (HIMS)LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a resultMay 22, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $98,349.15 in StockMay 21, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Irene Becklund Sells 943 SharesMay 15, 2024 | insidertrades.comSoleil Boughton Sells 2,503 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMay 14, 2024 | insidertrades.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 10,000 Shares of StockMay 13, 2024 | marketbeat.com3 Stocks That Suddenly Drew in Options TradersOptions are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their predictions on a particular stock.May 13, 2024 | marketbeat.com3 Stocks That Suddenly Drew in Options Traders (HIMS)Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside.May 29 at 2:16 PM | benzinga.comSmart Money Is Betting Big In HIMS OptionsMay 26, 2024 | fool.comThe Ultimate Growth Stock to Buy With $20 Right NowMay 26, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Stock Price Up 5.7%May 24, 2024 | theglobeandmail.comIs Hims & Hers Stock a Buy for GLP-1 Upside?May 24, 2024 | investorplace.com7 Stocks to Dominate in the Next Economic UpturnMay 23, 2024 | msn.comHims & Hers will sell knock-off Ozempic for $199 — and it won’t be approved by FDAMay 23, 2024 | msn.comCitigroup Downgrades Hims & Hers Health (HIMS)May 23, 2024 | markets.businessinsider.comNavigating 10 Analyst Ratings For Hims & Hers HealthMay 23, 2024 | investorplace.comMove Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.May 23, 2024 | americanbankingnews.comCitigroup Lowers Hims & Hers Health (NYSE:HIMS) to NeutralMay 23, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) PT Raised to $24.00 at Canaccord Genuity GroupMay 23, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider SellingMay 22, 2024 | finance.yahoo.comNvidia earnings, housing market outlook, BNPL regulatory pressure: Market DominationMay 22, 2024 | msn.comHims & Hers Is Now Selling Semaglutide: Here's What You Should KnowMay 22, 2024 | investorplace.comThe Growth Stock Shuffle: 2 to Ditch and 1 to OwnSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/31/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$15.69 High Stock Price Target$24.00 Low Stock Price Target$10.00 Potential Upside/Downside-19.2%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio107.89 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-0.24% Pretax Margin0.05% Return on Equity-0.70% Return on Assets-0.55% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.48 Sales & Book Value Annual Sales$959.40 million Price / Sales4.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book12.14Miscellaneous Outstanding Shares214,786,000Free Float176,747,000Market Cap$4.17 billion OptionableOptionable Beta0.97 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.98MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $1.01MMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $1.05MMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $928.7kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $54kMr. Mike Chi (Age 44)Chief Commercial Officer Comp: $998kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCAunaNYSE:AUNALifeMDNASDAQ:LFMDAirSculpt TechnologiesNASDAQ:AIRSSHL TelemedicineNASDAQ:SHLTView All CompetitorsInsiders & InstitutionsSoleil BoughtonSold 2,502 sharesTotal: $43,359.66 ($17.33/share)Farallon Capital Management LLCBought 1,634,000 shares on 5/24/2024Ownership: 0.780%Cetera Advisors LLCBought 25,605 shares on 5/24/2024Ownership: 0.012%Soleil BoughtonSold 4,915 sharesTotal: $98,349.15 ($20.01/share)Strategic Wealth Partners Ltd.Bought 54,204 shares on 5/20/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 15 analysts have issued 1 year price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $24.00. On average, they expect the company's share price to reach $15.69 in the next year. This suggests that the stock has a possible downside of 19.2%. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 at the beginning of the year. Since then, HIMS shares have increased by 118.2% and is now trading at $19.42. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a increase in short interest in May. As of May 15th, there was short interest totaling 22,130,000 shares, an increase of 20.3% from the April 30th total of 18,390,000 shares. Based on an average daily volume of 8,300,000 shares, the short-interest ratio is presently 2.7 days. Currently, 14.7% of the company's stock are short sold. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its earnings results on Monday, May, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The company earned $278.20 million during the quarter, compared to analysts' expectations of $270.37 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 0.70% and a negative net margin of 0.24%. The firm's quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) earnings per share. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Services ETF (XHS), iShares Virtual Work and Life Multisector ETF (IWFH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health issued an update on its second quarter 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $292.0 million-$297.0 million, compared to the consensus revenue estimate of $288.1 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.68%), Institutional Venture Management XVI LLC (2.43%), Institutional Venture Management XV LLC (2.43%), Redpoint Management LLC (2.36%), Farallon Capital Management LLC (0.78%) and Mckinley Capital Management LLC (0.30%). Insiders that own company stock include Alex Bard, Andrew Dudum, Christiane Pendarvis, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.